Teratogenicity by the hERG potassium channel blocking drug almokalant: Use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia

Toxicology and Applied Pharmacology

Volumn 193, Issue 2, 2003, Pages 168-176

  Danielsson, Bengt R ^a,b   Sköld, Anna Carin ^b   Johansson, Alf ^b   Dillner, Birgitta ^b   Blomgren, Bo ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Almokalant; Embryonic cardiac arrhythmia; hERG; Hypoxia; IKr; Teratogenicity

Indexed keywords

ALMOKALANT; BIOLOGICAL MARKER; PIMONIDAZOLE; POTASSIUM CHANNEL BLOCKING AGENT; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; FEMALE; GENE; HEART ARRHYTHMIA; HEART CONTRACTION; HEART RHYTHM; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NONHUMAN; TERATOGENICITY; VIDEOTAPE;

TRIXIS;

EID: 0345255947     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.07.002     Document Type: Article

References (52)

1. Abrahamsson C., Palmer M., Ljung B., Duker G., Bäärnhielm C., Carlsson L., Danielsson B. Induction of rhythm abnormalities in the fetal rat heart a tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant . Cardiovasc. Res. 28:1994;337-344.
2. Arteel G.E., Thurman R.G., Raleigh J.A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur. J. Biochem. 253:1998;743-750.
3. Arteel G.E., Thurman R.G., Yates J.M., Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver pimonidazole and retrograde perfusion of rat liver . Br. J. Cancer. 72:1995;889-895.
4. Azarbayjani F., Danielsson B.R. Phenytoin-induced cleft palate evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage . Teratology. 63:2001;152-160.
5. Azarbayjani F., Danielsson B.R. Embryonic arrhythmia by inhibition of HERG channels a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia. 43:2002;457-468.
6. Azuma C., Raleigh J.A., Thrall D.E. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat. Res. 148:1997;35-42.
7. Ban Y., Konishi R., Kawana K., Nakatsuka T., Fujii T., Manson J.M. Embryotoxic effects of L-691, 121, a class III antiarrhythmic agent, in rats. Arch. Toxicol. 69:1994;65-71.
8. Brent R.L., Franklin J.B. Uterine vascular clamping new procedure for the study of congenital malformations . Science. 132:1960;89-91.
9. Bronsky P.T., Johnston M.C., Sulik K.K. Morphogenesis of hypoxia-induced cleft lip in CL/Fr mice. J. Craniofacial Genet. Dev. Biol. Suppl. 2:1986;113-128.
10. Caplan A.I., Koutroupas S. The control of muscle and cartilage development in the chick limb the role of differential vascularization . J. Embryol. Exp. Morphol. 29:1973;571-583.
11. Carlsson L., Abrahamsson C., Andersson B., Duker G., Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant importance of infusion rate, QT dispersion, and early afterdepolarisations . Cardiovasc. Res. 27:1993;2186-2193. [see comments].
12. d'Argy R., Sperber G.O., Larsson B.S., Ullberg S. Computer-assisted quantification and image processing of whole-body autoradiograms. J. Pharmacol. Methods. 24:1990;165-181.
13. Danielsson B., Sköld A.C., Azarbayjani F., Öhman I., Webster W.S. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. Toxicol. Appl. Pharmacol. 163:2000;164-175.
14. Danielsson B.R. Malformations and fetal hypoxia induced by exaggerated pharmacological effects. Sundwall A., Danielsson B.R., Hagberg O., Lindgren E., Sjöberg P.A., Victor A. Developmental Toxicology Preclinical and Clinical Data in Restrospect. 1993;45-52 Tryckgruppen, Stockholm.
15. Danielsson B.R., Azarbayjani F., Sköld A.C., Webster W.S. Initiation of phenytoin teratogenesis pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation . Teratology. 56:1997;271-281.
16. Danielsson B.R., Iansdell K., Patmore L., Tomson T. Phenytoin and phenobarbital inhibit himan HERG potassium channels. Epilepsy Research. 55:2003;147-157.
17. Danielsson B.R., Sköld A.C., Azarbayjani F. Class III antiarrhythmics and phenytoin teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage . Curr. Pharmaceut. Design. 7:2001;787-802.
18. Danielsson B.R., Webster W.S. Cardiovascular active drugs. Kavlock R.J., Daston G.P. Drug Toxicity in Embryonic Development. II Advances in Understanding Mechanisms of Birth Defects Mechanistic Understanding of Human Developmental Toxicants . 1997;161-190 Springer, Berlin.
19. Dansky L.V., Finnell R.H. Parental epilepsy, anticonvulsant drugs, and reproductive outcome epidemiologic and experimental findings spanning three decades. 2 Human studies . Reprod. Toxicol. 5:1991;301-335.
20. Davies M.P., An R.H., Doevendans P., Kubalak S., Chien K.R., Kass R.S. Developmental changes in ionic channel activity in the embryonic murine heart. Circ. Res. 78:1996;15-25.
21. Desesso J.M. Comparative embryology. Hood R.D. Handbook of Developmental Toxicology. 1997;111-174 CRC Press, Boca Raton, FL.
22. Fantel A.G. Reactive oxygen species in developmental toxicity review and hypothesis . Teratology. 53:1996;196-217.
23. Fantel A.G., Person R.E., Tumbic R.W., Nguyen T.D., Mackler B. Studies of mitochondria in oxidative embryotoxicity. Teratology. 52:1995;190-195.
24. Finnell R.H., Dansky L.V. Parental epilepsy, anticonvulsant drugs, and reproductive outcome epidemiologic and experimental findings spanning three decades: 1 Animal studies . Reprod. Toxicol. 5:1991;281-299.
25. Franklin J.B., Brent R.L. The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old. J. Morphol. 115:1964;273-290.
26. Gilbert E.F., Bruyere H.J. Jr., Ishikawa S., Foulke L.M., Heimann S.R. Role of decreased cardiac output in isoproterenol-induced cardiovascular teratogenesis in chick embryos. Teratology. 21:1980;299-307.
27. Gomez H. The development of the innervation of the heart in the rat embryo. Anat. Rec. 130:1958;53-71.
28. Grabowski C.T. Embryonic oxygen deficiency a physiological approach to analysis of teratological mechanisms . Woollam D.H.M. Advances in Teratology. 1970;125-169 Logos Press, London.
29. Hancox J.C., Witchel H.J. Psychotropic drugs, HERG, and the heart. Lancet. 356:2000;428.
30. Kirby M.L. Cardiac morphogenesis recent research advances . Pediatr. Res. 21:1987;219-224.
31. Laboda L.A., Estroff J.A., Benacerraf B.R. First trimester bradycardia; a sign of impending fetal loss. J. Ultrasound Med. 8:1989;561-563.
32. Lee Y.M., Jeong C.H., Koo S.Y., Son M.J., Song H.S., Bae S.K., Raleigh J.A., Chung H.Y., Yoo M.A., Kim K.W. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo a possible signal for vessel development . Dev. Dyn. 220:2001;175-186.
33. Leist K.H., Grauwiler J. Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation. Teratology. 10:1974;55-67.
34. Malik M., Camm A.J. Evaluation of drug-induced QT interval prolongation implications for drug approval and labelling . Drug Saf. 24:2001;323-351.
35. Marks T.A., Terry R.D. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology. 54:1996;157-164.
36. Marvin W.J. Jr., Hermsmeyer K., McDonald R.J., Roskoski L.M., Roskoski R. Jr. Ontogenesis of cholingergic innervation in the rat heart. Circ. Res. 46:1980;690-695.
37. Rajala G.M., Kuhlmann R.S., Kolesari G.L. The role of dysrhythmic heart function during cardiovascular teratogenesis in epinephrine-treated chick embryos. Teratology. 30:1984;385-392.
38. Shigenobu K., Tanaka H., Kasuya Y. Changes in sensitivity of rat heart to norepinephrine and isoproterenol during pre- and postnatal development and its relation to sympathetic innervation. Dev. Pharmacol. Ther. 11:1988;226-236.
39. Sköld A.C., Danielsson B.R. Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol. Pharmacol. Toxicol. 88:2001;34-39.
40. Kr-blocker cisapride relation to embryonic cardiac arrhythmia . Reprod. Toxicol. 16:2002;333-342.
41. Spence S.G., Vetter C., Hoe C.M. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology. 49:1994;282-292.
42. Sweeney L.J., Clark E.B., Rosenquist G.C. Aortic arch anomalies in experimentally produced left heart hypoplasia. Pediatr. Res. 13:1999;487.
43. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 269:1995;92-95.
44. Vaccaro H., Amor F., Leyton M., Sepulveda W. Arrhythmia in early pregnancy a predictor of first-trimester pregnancy loss . Ultrasound Obstet. Gynecol. 12:1998;248-251.
45. Varia M.A., Calkins-Adams D.P., Rinker L.H., Kennedy A.S., Novotny D.B., Fowler W.C.J., Raleigh J.A. Pimonidazole a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma . Gynecol. Oncol. 71:1998;270-277.
46. Viragh S., Challice C.E. The development of the early atrioventricular conduction system in the embryonic heart. Can. J. Physiol. Pharmacol. 61:1983;775-792.
47. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
48. Wang L., Feng Z.P., Kondo C.S., Sheldon R.S., Duff H.J. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ. Res. 79:1996;79-85.
49. Webster W.S., Brown-Woodman P.D., Snow M.D., Danielsson B.R. Teratogenic potential of almokalant, dofetilide, and D-sotalol drugs with potassium channel blocking activity . Teratology. 53:1996;168-175.
50. Webster W.S., Lipson A.H., Brown-Woodman P.D. Uterine trauma and limb defects. Teratology. 35:1987;253-260.
51. Wellfelt K., Sköld A.C., Wallin A., Danielsson B.R. Teratogenicity of the class III antiarrhythmic drug almokalant role of hypoxia and reactive oxygen species . Reprod. Toxicol. 13:1999;93-101.
52. Werler M.M., Louik C., Mitchell A.A. Epidemiologic analysis of maternal factors and amniotic band defects. Birth Defects Res. A. 67:2003;68-72.